Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: A systematic review

Tarazona, S. Pérez; Galán, P. Solano; Alguacil, E. Bartoll; Diego, J. Alfonso

doi:10.1016/j.aller.2017.02.004

Cited by 25 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Keywords: cord blood cells, bronchopulmonary dysplasia, prevention, extremely preterm infants, autologous BACKGROUND Preterm birth, a significant growing health concern around the world, affects 5-18% of newborn infants (1,2). Bronchopulmonary dysplasia (BPD) is a severe and frustrating preterm complication causing adverse long-term outcomes (3,4). The incidence of BPD in extremely preterm neonates was reported to be as high as 68% (5).…”

Section: Clinical Trial Registrationmentioning

confidence: 99%

“…Currently, with the improvement of intensive care interventions, the mortality rate of extremely preterm neonates with BPD has decreased (7-9). However, many survivors still face a lifetime of disability, including long time dependence of oxygen therapy, asthma, and repeated hospital admission because of pneumonia even in developed countries (4,6). Although new ventilation strategies and pharmacological treatments have been applied, there are no curative therapies available to target the underlying structural changes of the lungs leading to the symptoms (3).…”

Section: Clinical Trial Registrationmentioning

confidence: 99%

See 1 more Smart Citation

Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT04440670]

Ren

Zhang

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

Background: Despite the rapid advance of neonatal care, bronchopulmonary dysplasia (BPD) remains a significant burden for the preterm population, and there is a lack of effective intervention. Stem cell depletion because of preterm birth is regarded as one of the underlying pathological mechanisms for the arrest of alveolar and vascular development. Preclinical and small-sample clinical studies have proven the efficacy and safety of stem cells in treating and preventing lung injury. However, there are currently no randomized clinical trials (RCTs) investigating the use of autologous cord blood mononuclear cells (ACBMNC) for the prevention of BPD in premature infants. The purpose of this study is to investigate the effects of infusion of ACBMNC for the prevention of BPD in preterm neonates <28 weeks.Methods: In this prospective, randomized controlled double-blind multi-center clinical trial, 200 preterm neonates <28 weeks gestation will be randomly assigned to receive intravenous ACBMNC infusion (5 × 10 7 cells/kg) or placebo (normal saline) within 24 h after birth in a 1:1 ratio using a central randomization system. The primary outcome will be survival without BPD at 36 weeks of postmenstrual age or at discharge, whichever comes Ren et al.Cord Blood Cells for Bronchopulmonary Dysplasia Prevention first. The secondary outcomes will include the mortality rate, other common preterm complication rates, respiratory support duration, length, and cost of hospitalization, and long-term outcomes after a 2-year follow-up.Conclusion: This will be the first randomized, controlled, blinded trial to evaluate the efficacy of ACBMNC infusion as a prevention therapy for BPD. The results of this trial will provide valuable clinical evidence for recommendations on the management of BPD in extremely preterm infants. Clinical Trial Registration:ClinicalTrials.gov, NCT03053076, registered 02/14/2017, retrospectively registered, https://register.clinicaltrials.gov/prs/app/ action/SelectProtocol?sid=S0006WN4&selectaction=Edit&uid=U0002PLA&ts=2&cx= 9y23d4 (Additional File 2).

show abstract

Section: Clinical Trial Registrationmentioning

confidence: 99%

Section: Clinical Trial Registrationmentioning

confidence: 99%

Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT04440670]

Ren

Zhang

et al. 2020

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…About 50% of pneumonia and about 90% of bronchiolitis in children is caused by respiratory the syncytial virus (RSV), the infection of which in children with bronchopulmonary dysplasia is often associated with the need for hospitalization and MV, which in turn leads to pulmonary dysfunction. RSV infection in children with BPD also poses a significant risk of developing bronchial hyperreactivity and bronchial asthma [111][112][113][114].…”

Section: Long-term Prognosis and Disease Complications In Patients Wimentioning

confidence: 99%

Pathophysiological mechanisms and pharmacological methods of prevention and treatment of bronchopulmonary dysplasia in preterm infants

Wątroba¹,

Bryda²

2019

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Wątroba S. J, Bryda J. Pathophysiological mechanisms and pharmacological methods of prevention and treatment of bronchopulmonary dysplasia in preterm infants. AbstractIntroduction. Bronchopulmonary dysplasia (BPD) is a respiratory disease that is characterized by long-term respiratory failure and mainly affects premature infants with low birth weight (LBW), undergoing mechanical ventilation (MV) or requiring long-term oxygen therapy. In Europe, among newborns with birth weight <1500g, the incidence of BPD is around 15%. Objective. The purpose of this review was to analyze the pathophysiological mechanisms involved in the development of BPD in premature newborns and to discuss the current possibilities of pharmacological prevention and treatment of BPD. Description of the state of knowledge. The BPD pathogenesis is multifactorial. Lung damage is the result of barotrauma and volutrauma due to high-performance MV, actions of reactive oxygen species (ROS) and infectious agents. Currently used methods of pharmacological treatment of severe forms of BPD are mainly based on systemic steroid therapy and can not be considered completely effective and free of side effects. Conclusion. Despite the widespread use of proper pharmacotherapy and dynamic development of new methods of respiratory therapy, mortality in BPD is estimated at around 10% -20%. Infants with BPD are much more exposed to respiratory infections caused by respiratory syncytial virus (RSV), which may result in the development of bronchial hyperresponsiveness and bronchial asthma. Among children with BPD there are significantly higher cognitive and behavioral deficits compared to healthy children, and cerebral palsy is also significantly more common.Abbreviations AA -arachidonic acid; AAP COFN -Committee on Foetus and Newborn of the American Academy of Pediatrics; ACTHadrenocorticotropin; ADH -vasopressin, antidiuretic hormone; ASMC -airway smooth muscle cells; BPD -bronchopulmonary dysplasia; BTN -betamethasone; CAT -catalase; CC10 -Clara cell 10 kDa protein; CLD -chronic lung disease; COXcyclooxygenase; CPAP -continuous positive airway pressure; CPS FNC -Fetus and Newborn Committee of the Canadian Pediatric Society; DEX -dexamethasone; ELBW -extremely low birth weight; ENA-78 -epithelial protein activating neutrophils; EURAIL -Europe Against Immature Lung; FC -fludrocortisone; FiO 2 -oxygen concentration in the breathing mixture; FTP -fluticasone propionate; GCSs -glucocorticosteroids; GM-CSF -granulocyte and macrophage colonystimulating factor; GPx -glutathione peroxidase; HC -hydrocortisone; HO . -hydroxyl radical; HO 2 . -hydroperoxide radical; IFN-γ -gamma interferon; ILs -interleukins; IRDS -respiratory distress syndrome; IUGR -intrauterine growth retardation; IVH -intraventricular haemorrhage; LBW -low birth weight; LTs -leukotrienes; MAS -meconium aspiration syndrome; MIP-1 -macrophage inflammatory protein-1; MMPs -metalloproteinases; MRI -magnetic resonance imaging; MV -mechanical ventilation; n-CPAP -continuous positive airway pressure -nasal metho...

show abstract

“…К возрасту трех лет БЛД заканчивается клиническим выздоровлением либо трансформируется в хроническую респираторную патологию [3]. К неблагоприятным исходам БЛД относят рецидивирующий бронхит, хронический бронхит, облитерирующий бронхиолит [5], бронхиальную астму [6].…”

Section: Introductionunclassified

The capability of chest computed tomography in the diagnosis of bronchopulmonary dysplasia outcomes in premature infants

Павлинова¹,

Киршина²,

Сахипова³

et al. 2019

Med. sov.

View full text Add to dashboard Cite

Purpose of the study was to establish clinical and radiological features of bronchopulmonary dysplasia (BPD) outcomes in children. Materials and methods. A prospective follow-up study of 132 premature infants with infant respiratory distress syndrome (IRDS) was analyzed. BPD was developed in 66 cases. At a late childhood, clinical and radiological outcomes of the transferred conditions were diagnosed on the basis of anamnesis, clinical examination, and results of chest computed tomography (CT). Results. Clinical recovery was observed significantly more frequently in the outcome of IRDS without BPD development (69.6% versus 31.8% in the case of BPD development). In patients with BPD in the anamnesis, the odds ratio of asthma developed in the late childhood was 5.304 times higher than in children who had IRDS. The majority (62 cases, 93.9%) of children who had IRDS did not have structural changes in lung tissue according to CT (p = 0.000), 21 (31.8%) children with BPD had abnormal CT. In BPD, typical radiological findings were hypoattenuated lung areas (p = 0.020) and areas of pulmonary fibrosis (p = 0.016). Conclusion. Chest CT could be assigned to the patients with BPD in the anamnesis to assess lung tissue structural changes and diagnose outcomes of the disease.

show abstract

Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: A systematic review

Cited by 25 publications

References 47 publications

Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT04440670]

Use of Autologous Cord Blood Mononuclear Cells Infusion for the Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: A Study Protocol for a Placebo-Controlled Randomized Multicenter Trial [NCT04440670]

Pathophysiological mechanisms and pharmacological methods of prevention and treatment of bronchopulmonary dysplasia in preterm infants

The capability of chest computed tomography in the diagnosis of bronchopulmonary dysplasia outcomes in premature infants

Contact Info

Product

Resources

About